BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ProNAi Therapeutics, Inc. Cleared to Begin Phase I Clinical Trials for the First DNA Interference (DNAi(R)) Therapeutic


3/20/2008 6:20:13 AM

KALAMAZOO, Mich.--(BUSINESS WIRE)--ProNAi Therapeutics, Inc., a biopharmaceutical development stage company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi®), today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to proceed into Phase I clinical trials with its first drug candidate, PNT2258.

Robert Forgey, Acting CEO of ProNAi Therapeutics, Inc., said, “We are pleased and very proud to announce that PNT2258 has been accepted by the FDA for Phase I human safety trials. This is an important milestone in developing therapies to treat diseases via the novel class of nucleic acid drugs represented by DNAi®. ProNAi has brought PNT2258 from idea to open IND in just a few years, pioneering an entirely new type of nucleic acid therapeutic. We have kept pace with RNAi-based approaches and are utilizing a novel, potentially breakthrough technology, to safely and effectively administer PNT2258.”

In preclinical research, PNT2258 has shown promising single agent efficacy, combination therapy efficacy and relevant drug-dose response for multiple cancer types including both hematological and solid tumors.

ProNAi Scientific Advisory Board Member Cy Stein, MD, PhD, Professor and Head Genitourological Cancer at the Albert Einstein College of Medicine, said, “The filing and approval of the ProNAi IND represents a substantial step forward in oligonucleotide therapeutics.”

ProNAi has partnered with Novosom AG and Polymun AG to develop liposome-based technologies to deliver the company’s unique DNAi® oligonucleotides. The company has also partnered with New York-based Foundation Ventures, an investment banking firm that will assist in coordinating ProNAi’s upcoming fundraising efforts in support of DNAi® and PNT2258.

Mina Sooch, Partner at Apjohn Ventures and Founding ProNAi Investor and Board member said, “The investors are very pleased with this significant achievement. PNT2258 is one of the first systemically delivered DNAi therapeutics in a very high profile field, and the FDA’s clearance for safety trials is a major initial validation on the road ahead toward further testing and development.”

About ProNAi Therapeutics, Inc. and DNAi®

ProNAi Therapeutics, Inc. is a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi®), a novel approach of utilizing single strands of DNA oligonucleotides to target genomes responsible for complex diseases, such as cancer and other inflammatory diseases. ProNAi is currently developing multiple DNAi®-based drug candidates with the potential to treat multiple cancers. The company’s lead drug candidate, PNT2258, which has demonstrated in vivo efficacy in a variety of preclinical tumor xenograft models, and has been cleared for Phase I clinical trials by the FDA.

ProNAi is based in Kalamazoo, Michigan. For more information, please visit: www.pronai.com or contact Robert Forgey at 269-372-3289.

About Foundation Ventures, LLC

Foundation Ventures is an investment banking firm focused on obtaining venture capital financing for promising companies within the Life Science industry. Foundation represents companies and has a network of institutional investors throughout the United States, Europe and Asia.

Foundation Ventures is based in New York City. For more information, please visit: www.foundationventures.com or contact Joseph Lucchese at 212-956-2151.

Contact: Aviator PR Mario Fante, 617-763-9887 mario@aviator-pr.com

Source: ProNAi Therapeutics, Inc.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES